PBAC okays lenalidomide in newly diagnosed multiple myeloma

The latest positive recommendations from PBAC include an extension of indication for lenalidomide to patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for a primary stem cell transplant. At its August 2019 meeting, the PBAC recommended the listing of lenalidomide in combination with bortezomib and dexamethasone (RVd) for the treatment of patients with ...

Already a member?

Login to keep reading.

© 2021 the limbic